The Ebola Virus Disease: A Global Health

Crisis
Abstract

Ebola Virus Disease (EVD), first identified in 1976, is a severe, often fatal illness in humans,
caused by the Ebola virus. Since its emergence, Ebola has led to numerous outbreaks across
Africa, with the most significant outbreak occurring between 2013 and 2016 in West Africa,
where it claimed over 11,000 lives. The disease is characterized by rapid onset of symptoms such
as fever, vomiting, diarrhea, hemorrhaging, and in some cases, multi-organ failure. The high case
fatality rate, combined with the rapid transmission and lack of effective treatment options during
early outbreaks, made Ebola an international public health emergency. This journal reviews the
history, epidemiology, clinical presentation, and public health response to Ebola, while analyzing
the development of treatments and vaccines and the broader implications for global health
security.

Introduction

Ebola Virus Disease (EVD) is a highly contagious viral hemorrhagic fever that has caused
significant morbidity and mortality since its discovery in 1976. The virus is transmitted through
direct contact with the blood, bodily fluids, or tissues of infected persons, or through
contaminated objects. Outbreaks have primarily occurred in African countries, but the disease
poses a global threat due to its potential for international spread. Ebola's high case fatality rate,
rapid progression, and lack of initial effective treatment methods led to widespread panic during
past outbreaks.

The 2013–2016 West Africa Ebola outbreak became the largest and most complex in history,
affecting thousands of individuals and overwhelming public health systems in affected countries.
Although significant progress has been made in understanding the virus, developing diagnostic
tools, and deploying vaccines, Ebola remains a global health concern due to its potential to cause
future outbreaks. This journal explores the origins, clinical features, transmission routes, public
health response, and treatment strategies associated with Ebola Virus Disease.

History and Origins of Ebola

Initial Discovery

Ebola Virus was first identified in 1976 during two simultaneous outbreaks in Sudan and the
Democratic Republic of Congo (then Zaire), near the Ebola River, which is how the virus got its
name. The initial cases were characterized by high fever, bleeding, and rapid deterioration of
health, often leading to death. The virus is believed to have originated from animals, particularly
fruit bats, which serve as the natural hosts for Ebola. Humans can become infected through direct
contact with the bodily fluids of infected animals or through person-to-person transmission in
outbreaks.
The 2013-2016 West Africa Outbreak

The 2013–2016 West Africa outbreak was the largest Ebola outbreak to date, affecting the
countries of Guinea, Liberia, and Sierra Leone. This epidemic resulted in over 28,000 reported
cases and more than 11,000 deaths, with the disease spreading to other countries, including the
United States, Spain, and the United Kingdom. The outbreak's magnitude was exacerbated by
weaknesses in the public health systems of affected countries, widespread fear and
misinformation, and difficulties in controlling the virus due to its highly contagious nature.

During this outbreak, the virus spread through direct contact with an infected person's blood or
fluids, making containment challenging. Health care workers, who were at the front lines of the
response, were especially vulnerable. The epidemic prompted an international response,
including support from organizations like the World Health Organization (WHO), Médecins
Sans Frontières (MSF), and the United Nations, but the crisis revealed serious gaps in global
preparedness and response to emerging infectious diseases.

Clinical Features of Ebola Virus Disease

Symptoms and Pathophysiology

Ebola Virus Disease typically presents with nonspecific flu-like symptoms in the early stages,
including:

 Sudden onset of fever

 Severe headache
 Muscle pain
 Weakness
 Fatigue
 Sore throat

As the disease progresses, symptoms can include vomiting, diarrhea, rash, impaired liver and
kidney function, and internal and external bleeding. The clinical course of EVD is highly
variable, but in many cases, the infection leads to multi-organ failure, hemorrhagic shock, and
death. The high case fatality rate—between 25% and 90%, depending on the outbreak—further
underscores the severity of the disease.

Transmission

Ebola is transmitted through direct contact with the blood or bodily fluids of an infected person
or animal. The virus can also be spread through contaminated objects, such as needles and other
medical equipment, if proper precautions are not followed. Additionally, the virus can be
transmitted from an infected person to a fetus during pregnancy or through breastfeeding.
Importantly, Ebola is not airborne and cannot be spread through casual contact, such as through
coughing or sneezing.
Human-to-human transmission occurs primarily in healthcare settings, particularly when
personal protective equipment (PPE) is inadequate. This is why health care workers are
particularly at risk, as evidenced by the high number of infections among medical staff during
past outbreaks.

Public Health Response to Ebola Outbreaks

Early Containment Efforts

In the early outbreaks of Ebola, containment strategies focused primarily on isolation of infected
patients and the identification of contacts. However, limited healthcare infrastructure, poor
awareness about the disease, and delays in response mechanisms contributed to the rapid spread
of the virus. Contact tracing, quarantine measures, and community engagement were key
strategies employed during the 2013-2016 outbreak in West Africa.

The role of international organizations, such as the WHO, the Centers for Disease Control and
Prevention (CDC), and Médecins Sans Frontières, was critical in providing assistance to affected
countries, with rapid deployment of medical teams, supplies, and experts. However, the
international response was slow at the beginning of the outbreak, allowing the virus to spread
significantly before containment efforts were fully implemented.

Vaccination and Treatment Development

One of the most notable outcomes of the 2013-2016 Ebola outbreak was the rapid development
and deployment of Ebola vaccines. The rVSV-ZEBOV vaccine, which showed high efficacy in
clinical trials, became the first licensed Ebola vaccine in 2019. During the outbreak, several
experimental treatments were also used, such as ZMapp (a monoclonal antibody cocktail),
Favipiravir, and Remdesivir—all of which showed promise in treating Ebola infections, though
the efficacy of these treatments was initially unclear due to limited clinical data.

The development of an effective vaccine was seen as a breakthrough in the fight against Ebola.
The vaccine was deployed in "ring vaccination" strategies, where close contacts of confirmed
cases were vaccinated to prevent further transmission. As of today, the rVSV-ZEBOV vaccine
remains one of the most important tools in Ebola control.

Global Implications and Lessons Learned

Gaps in Global Preparedness

The 2013-2016 outbreak exposed several critical gaps in global health security, including:

1. Weak Healthcare Systems: In many affected countries, healthcare infrastructure was

insufficient to cope with the scale of the Ebola outbreak.
2. Slow Response: The initial international response was slow, which allowed the virus to
spread beyond the borders of affected countries.
 3. Misinformation and Stigma: Fear, misinformation, and stigma surrounding Ebola
discouraged people from seeking treatment and adhering to preventive measures.

The outbreak underscored the need for improved preparedness for future epidemics. Global
health bodies have since focused on strengthening health systems, improving surveillance, and
ensuring rapid deployment of resources and personnel in the event of an outbreak.

Ongoing Research and Future Challenges

While the development of vaccines and treatments has been a major advancement, challenges
remain. The ability to rapidly deploy vaccines in resource-limited settings is a continuing
concern, and more research is needed to improve the efficacy and distribution of therapeutic
interventions. Additionally, the risk of future Ebola outbreaks persists, as the virus can be
transmitted through contact with infected wildlife, such as fruit bats, which continue to serve as
natural reservoirs for the virus.

Conclusion

Ebola Virus Disease remains a severe global health threat with the potential for future outbreaks.
The 2013-2016 West Africa outbreak was a stark reminder of the vulnerabilities of global health
systems and the need for increased preparedness. While significant progress has been made in
understanding and controlling Ebola through the development of vaccines and treatments,
lessons learned from this outbreak should guide future responses to emerging infectious diseases.

The global community must continue to strengthen healthcare infrastructure, improve early
warning systems, and ensure equitable access to vaccines and treatments to prevent future Ebola
outbreaks from reaching pandemic proportions.

References

1. World Health Organization (WHO). (2016). "Ebola Virus Disease." Retrieved from
www.who.int.
2. Frieden, T. R., & Daskalakis, D. (2016). "Ebola: A Global Health Emergency." The
Lancet, 387(10020), 1836-1838. https://doi.org/10.1016/S0140-6736(16)00225-2
3. Gire, S. K., Gire, E. A., Tambo, E., & Liu, L. (2015). "The Genetic Diversity of Ebola
Virus." The New England Journal of Medicine, 373(5), 434-444.
4. Johnson, K. M., & Johnson, B. K. (2015). "The Ebola Virus: A Historical Overview."
The Journal of Infectious Diseases, 212(S1), S4-S8.
5. Van Kerkhove, M. D., Wilder-Smith, A., & Cameron, M. (2019). "Ebola: An Ongoing
Challenge to Global Health." PLOS Neglected Tropical Diseases, 13(8), e0007505.
https://doi.org/10.1371/journal.pntd.0007505